Microglia constitute about 10% to 12% of the total cells of the brain 7 and are located predominantly in the gray matter, including the hippocampus, olfactory telencephalon, basal ganglia, and substantia niagra in the normal adult brain. 8 In the healthy brain, microglia interact with other cortical elements such as astrocytes, neurons, and blood
Injury to the central nervous system is characterized by localization of activated microglia at the site of injury. The peripheral benzodiazepine receptor expressed on the outer mitochondrial membrane of the activated microglia is a sensitive biomarker for the detection of this neuroinflammatory response to an insult. PK11195, an isoquinoline ligand that specifically binds peripheral benzodiazepine receptor, can be tagged with a positron emitter and used as a tracer for molecular imaging of this receptor in vivo by positron emission tomography (PET). [ 11 C](R)PK11195 has been used in the imaging of various neuroinflammatory disorders, such as Alzheimer disease and multiple sclerosis. On the basis of our small-animal PET imaging studies using a neonatal rabbit model of maternal inflammation-induced cerebral palsy, we propose that PET imaging using [ 11 C](R)PK11195 may be a valuable tool for detecting neuroinflammation in the brain of newborns born to mothers with chorioamnionitis.
Keywords: PET; neuroinflammation T he inflammatory response in the brain has been implicated in the development of a number of neurodegenerative disorders, both in children and in adults. Maternal intrauterine inflammation has been recognized as one of the causes of perinatal brain injury leading to periventricular leukomalacia, resulting in lifelong disabilities such as cerebral palsy and cognitive impairment in the infant. 1 Recent evidence has shown that activated microglia may trigger white matter injury in the perinatal period. [2] [3] [4] Intrauterine infection may lead to a fetal systemic inflammatory response mediated by cytokines, resulting in the activation of microglial cells in the fetal brain. Microglial cells, when activated by proinflammatory cytokines, release oxidative and nitrosative products, and excitotoxic metabolites that can damage surrounding oligodendrocytes. 5, 6 This neuroinflammatory response to perinatal insults can be detected at an early stage by positron emission tomography (PET), using ligands that are specific for the peripheral benzodiazepine receptors expressed by microglial cells. We describe the characteristics of the inflammatory response in the central nervous system that make it amenable for detection by PET imaging and review its current applications in the detection of various neurodegenerative and neuroinflammatory disorders in animal models and in patients. We also discuss potential applications of PET imaging in detecting neuroinflammation induced by perinatal brain injury in the neonatal period. vessels, thereby monitoring neuronal well-being. The resident microglia are characterized by ramified morphology and spiky protrusions. 9 They are highly dynamic structures and can sense subtle changes in their microenvironment with their motile processes and protrusions. 10 On activation after an injury, microglia undergo a pronounced change in morphology from ramified to an ameboid structure presumably serving an immune surveillance function. Activated microglia secrete proinflammatory mediators such as prostaglandins, tumor necrosis factor-a, interleukin-1b, chemokines, reactive oxygen species, nitric oxide, and anti-inflammatory substances such as interleukin-10 and neurotrophic factors. 9 In the developing brain, microglia are predominantly seen in the white matter tracts from late second trimester onward until term, decreasing in density in the postnatal period but present in low densities in the white matter tracts until 2 years of age. The microglia then migrate to the cortex where they are found mostly during adulthood, taking on their typical ramified form. 11 Although it is still not clear if the presence of activated microglia in many neuroinflammatory disorders is the cause or the effect, its detection can be used as a reliable biomarker for brain injury. Activated microglial cells express the peripheral benzodiazepine receptor on the outer membrane of the mitochondria that can be used as a sensitive marker for the presence of neuroinflammation.
Role of Inflammation in Neurological Disorders
The inflammatory response of the central nervous system to various types of injuries is dominated by the presence of activated microglia and astrocytes (reactive gliosis) at the site of injury. 12, 13 Although the primary goal of this neuroinflammatory response may be related to repair and regeneration, it can act as a double-edged sword, attenuating the neuronal injury on one hand, while on the other hand exacerbating the underlying pathology. This neuroinflammatory process may also disrupt the blood-brain barrier, resulting in the entry of cells such as peripheral macrophages and neutrophils from the bloodstream at the site of injury. 14 Microglial cells can act as both the target and source of pro-inflammatory cytokines 15 and have been implicated in the development and progression of various neurodegenerative and neuroinflammatory disorders such as multiple sclerosis, Parkinson disease, Alzheimer disease, and experimental autoimmune encephalitis. [16] [17] [18] [19] The role of microglia in neurodegenerative disorders such as Alzheimer disease has been investigated extensively. In vivo imaging and quantitative morphological analysis in transgenic mice have demonstrated that microglia can aggregate around amyloid plaques and phagocytose A b proteins. 20 Microglia isolated from aged transgenic mice models of Alzheimer disease exhibit marked reduction of Ab binding scavenger receptors and Ab-degrading enzymes along with an increase in the proinflammatory cytokines interleukin-1b and tumor necrosis factor-a, thereby setting the stage for disease progression. 21 Similarly, in Parkinson disease, even though the etiology of the disease remains largely elusive, presence of an enduring neuroinflammation is strongly suspected, with activated microglia found in close proximity to degenerating dopaminergic neurons. 22 In the pediatric age group, microglial activation has been implicated in the development of disorders such as epilepsy, autism, leukodystrophies, and chorioamnionitisinduced cerebral palsy. 1, [23] [24] [25] Activated microglia have been detected in children with encephalitis and intractable seizures and also in animal models of seizures induced by excitotoxic metabolites. [26] [27] [28] An active neuroinflammatory response characterized by microglial activation and astroglia was noted in the cerebral cortex, white matter, and cerebellum of patients with autism, along with increased cerebrospinal fluid expression of inflammatory cytokines. 25 An increased expression of proinflammatory cytokines colocalizing with the presence of activated microglia, astrocytes, and globoid cells was noted in macaques affected by globoid cell leukodystrophy. 29 Inflammatory infiltrates involving activated microglia were also noted in the brain of patients with X-linked adrenoleukodystrophy. 30 
Neuroinflammation in Cerebral Palsy
A number of clinical studies have noted the significant correlation between intrauterine inflammation, perinatal brain injury, and cerebral palsy. 31, 32 Clinical evidence indicates that the presence of periventricular leukomalacia is one of the most identifiable risk factors for developing cerebral palsy. 33 Periventricular leukomalacia may be focal, characterized by areas of necrosis in the deep white matter near the ventricles, or diffuse throughout the cerebral white matter, with injury to developing oligodendrocytes and presence of activated microglial cells. [34] [35] [36] In recent years, a number of in vitro and in vivo studies have implicated microglial cells in the development of periventricular leukomalacia. Haynes and colleagues 34 have shown the increased presence of activated microglia diffusely throughout the white matter in autopsy specimens of patients with periventricular leukomalacia, indicating that microglia are involved in causing white matter damage by oxidative and nitrosative stress. Several compelling studies have shown the correlation between elevated amniotic fluid concentrations of cytokines and the subsequent development of periventricular leukomalacia and cerebral palsy. 37, 38 Proinflammatory cytokines such as interleukin-1b and tumor necrosis factor-a have been found in high concentrations in the amniotic fluid of women with preterm labor and intra-amniotic fluid infection. 39 High levels of tumor necrosis factor-a, interleukin-1b, and interleukin-6 have been detected in the blood of neonates that develop spastic cerebral palsy. 40 Infants with periventricular leukomalacia and a history of infection have high cerebral cytokine levels, such as tumor necrosis factor-a and interleukin-1b. 41 Proinflammatory cytokines such as interleukin-1b and tumor necrosis factor-a have been shown to induce microglial activation in vitro. 42 The fetal inflammatory response after intrauterine infection/inflammation may lead to activation and recruitment of microglial cells present in the white matter regions of the fetal brain, subsequently resulting in widespread production of proinflammatory mediators and leading to the death of surrounding oligodendrocytes and, hence, white matter injury ( Figure 1 ).
In vitro studies supporting the role of microglial cell activation in white matter injury have shown that lipopolysaccharide treatment results in oligodendrocyte damage only in the presence of microglial cells. 43 Activated microglial cells may induce oligodendrocyte injury by releasing superoxides and peroxynitrites, 6 excitotoxic metabolites such as glutamate and quinolinic acid that may cause glutamate-receptor-or NMDA-receptor-mediated injury to oligodendrocytes, 5 and by producing a variety of proinflammatory cytokines, many of which are cytotoxic. 44 Studies have demonstrated selective white matter lesions in fetal and neonatal animals after local, systemic, or intrauterine administration of lipopolysaccharide. 45 Activated microglia express toll-like receptors that are pivotal for recognizing microbial motifs expressed by a wide array of pathogens. 46 The toll-like receptor 4 receptors on microglia recognize the bacterial lipopolysaccharide and are essential for lipopolysaccharide-induced oligodendrocyte death. 43 It is shown that peroxynitrite, a short-lived potent oxidant and the reaction product of nitric oxide and superoxide, is the toxic microglial factor responsible for lipopolysaccharide-induced death of preoligodendrocytes. 6 The low resistance of oligodendrocytes to oxidative stress, presence of calcium permeable glutamate receptors, and Figure 1 . Proposed mechanism of oligodendrocyte and white matter injury in maternal intrauterine infection. The figure illustrates oligodendrocyte damage and microglial activation in response to cytokines after lipopolysaccharide exposure in the mother. Lipopolysaccharide exposure in the mother after maternal intrauterine infection results in the release of proinflammatory cytokines. These cytokines may cross the blood-brain barrier, resulting in the activation of the microglial cells and leading to a change in morphology to an ameboid form from a more ramified form. The activated microglia overexpress peripheral benzodiazepine receptors located in the outer wall of the mitochondria that can be imaged using [ 11 C](R)PK11195 by positron emission tomography (PET). Release of reactive oxygen species, reactive nitrogen species, and cytokines by the activated microglia may lead to the arrest of oligodendrocyte progenitors. Inability of oligodendrocyte to produce myelin may subsequently lead to hypomyelination of neurons and white matter injury, causing periventricular leukomalacia.
the presence of N-methyl-D-aspartate (NMDA) receptors in their myelinating processes make them highly susceptible for injury. 47, 48 Studies in our laboratory have shown that intrauterine administration of endotoxin to pregnant rabbits near term led to a robust activation of microglial cells confined to the periventricular white matter regions of the newborn rabbit brain that were associated with a phenotype of cerebral palsy and hypomyelination in the neonate. 4 Dammann and Leviton 31 have proposed that periventricular leukomalacia and cerebral palsy may develop as a result of an ongoing inflammatory process, as evidenced by the presence of inflammatory markers weeks after birth and activated microglia on autopsy even in adults with perinatal brain injury.
Peripheral Benzodiazepine Receptor or Translocator Protein 18 kd: A Biomarker for Activated Microglia
The peripheral benzodiazepine-binding sites or receptor are multimeric protein complexes comprising 3 subunits. 49 These binding sites were originally discovered in rat kidneys because diazepam was found to bind these receptors with high affinity. 50 Although these sites bind benzodiazepines, they are pharmacologically and structurally different from the central benzodiazepine receptors, with different physiological functions. 51 Because of its significant difference from the central benzodiazepine receptors, it has been proposed that the nomenclature of the peripheral benzodiazepine receptor should be changed to translocator protein 18 kd to be more reflective of its function. 52 These sites are now known to comprise the 18-kd receptor protein, the 32-kd voltage-dependent anion channel receptor protein required for benzodiazepine binding, and the 30-kd adenine nucleotide carrier. 51, 53 They are most commonly located in the outer mitochondrial membrane of activated microglia in the brain 54 and have been used as a sensitive marker to visualize and measure glial cell activation associated with various neuroinflammatory disorders. 26, 55, 56 Although the exact function of the peripheral benzodiazepine receptor has not been clearly elucidated, it appears that peripheral benzodiazepine receptor is involved in the regulation of cell death, 57 mitochondrial respiration, 58 cell growth and proliferation, 59 steroidogenesis, 53 and chemotaxis and cellular immunity. 60, 61 The normal healthy brain does not express peripheral benzodiazepine-binding sites except in areas such as the choroid plexus, ependymal layer, and perivascular cells. 55 In the presence of brain injury, the activation of microglial cells is typically localized to the site of the injured neuron, with extension along the anterograde or retrograde axonal pathway. This characteristic response helps localize the site and distribution of injury accurately when imaging activated microglia, providing information about the temporal and spatial progression of various neuroinflammatory disorders.
Although in vitro studies have shown that peripheral benzodiazepine receptor expression may be seen in both astrocytes and microglia, many in vivo studies have shown that increased expression of peripheral benzodiazepine receptor after an injury has primarily correlated most consistently with the presence of activated microglial cells. 26, 62, 63 The extent of peripheral benzodiazepine receptor expression appears to be directly related to the extent of injury, with a large increase noted in the case of frank neuronal loss and smaller increases noted with just the loss of neuronal terminals. 64, 65 Detection of peripheral benzodiazepine receptor expression also appears to be a more sensitive indicator of brain injury, leading to an increase even before histological changes such as neuronal apoptosis or loss are noted. 64 Benzodiazepines such as 7-chloro-5-(4-chlorophenyl)-1-methyl-1,3-dihydrobenzo [1, 4] diazepin-2-one (Ro5-4864), bind the peripheral benzodiazepine receptor with nanomolar affinity, with weaker affinity for the central benzodiazepine receptors. Other classes of compounds such as isoquinolines, phenoxyphenyl acetamides, pyrazolopyrimidine, indoleacetamide, and imidiazopyridines also bind peripheral benzodiazepine receptors, having the potential to be developed as biomarkers for the presence of activated microglial cells in brain injury. 66, 67 
Positron Emission Tomography Imaging of Activated Microglial Cells With [ 11 C](R) PK11195
The constitutively low expression of peripheral benzodiazepine receptors in the normal brain with increased expression localized to the site of injury makes it an attractive biomarker for the detection of neuroinflammation and brain injury by imaging. Isoquinoline ligands such as PK11195
(1-[2-chlorophenyl]-N-methyl-N-[1-methylpropyl]-3-isoquinoline carboxamide) bind the 18-kd subunit of the peripheral benzodiazepine-binding site 68 expressed on activated microglial cells. When labeled with carbon-11, PK 11195 can be effectively used as a ligand for PET studies, indicating the presence of activated microglia in acute inflammatory and neurodegenerative disorders (Table 1) . 56, 62, 69 The (R) enantiomer has been shown to have higher affinity for the peripheral benzodiazepinebinding sites than the (S) enantiomer 87 and, therefore, the [ 11 C](R)-PK11195 is used in most studies.
In our study, we demonstrated increased retention of [ 11 C](R)PK11195, indicating specific binding of the tracer to peripheral benzodiazepine receptors in activated microglial cells in the newborn rabbit brain exposed to endotoxin in utero ( Figure 2) . The increase in [ 11 C](R)PK11195 retention also correlates with our immunohistological studies, which demonstrates a change in morphology from ramified to ameboid microglia ( Figure 3A ) and a robust increase in ameboid microglial cells in the periventricular white matter regions in these animals ( Figure 3B ). 4, 88 The longitudinal assessment of [ 11 C] PK11195 binding kinetics can be used as an effective tool in following the evolution of microglial activation in periventricular leukomalacia and to determine the optimal time period for institution of therapy and to follow response to treatment.
[ 11 C](R)-PK11195 PET imaging in animal models of disease in models of Parkinson disease, cuprizoneinduced demyelination, traumatic brain injury, stroke, and cerebral palsy have been useful for demonstrating the presence of activated microglia in these models. 63, 70, [88] [89] [90] The use of small animal PET provides a unique approach for conducting longitudinal studies in the same animal to determine the temporal progression of the disease and to monitor response to novel therapies.
The ligand PK11195 is effective in determining the cellular response in central nervous system pathology because of the fact that its entry into the brain from the blood is rapid and is not dependent on the blood-brain barrier. 91 The in vivo PET signal and hence quantification of PK11195 binding may vary depending upon cerebral blood flow, which may be increased in certain regions because of inflammation or decreased globally because of sepsis and poor cardiac output. Changes in bloodbrain barrier permeability and recruitment of peripheral macrophages may also dictate the amount of tracer uptake in the brain. Lammertsma and Hume 92 used a simplified reference tissue model to determine the binding potential of [ 11 C] PK11195, in which the ratio of the rate constant with which the tracer binds in the diseased region to a reference healthy area and the rate constant of dissociation or washout from these regions is calculated to estimate the specific binding of the tracer in the affected region. In our animal model, because of the small size of the brain and potential errors in manually defining disease-free regions, Cagnin et al 73 Increased [ 11 C](R)-PK11195-PET was observed within the affected limbic system and additionally in areas connected to the limbic system by neural pathways, including the lingual gyrus in the occipital lobe and the inferior parietal lobe Banati 26 Increased binding of [ 11 C](R)-PK11195 in patients with Rasmussen encephalitis throughout the affected hemisphere NOTE: PET ¼ positron emission tomography. a semiquantitative estimation of specific binding was determined by comparing [ 11 C](R)PK11195 retention in the whole brain over time, in the newborns with neuroinflammation versus the controls. 88 Recently, tracers developed using other ligands such as PK11195 with less signal-to-noise ratio. 90, 93 Clinical Application of [ 11 C](R)PK11195 Imaging in Perinatal Brain Injury Ameboid microglial cells accumulate in the immature white matter through the end of the second trimester until term as part of normal development, decreasing in density toward term but maintaining their morphology even in early infancy. 11, 94, 95 These microglial cells eventually migrate toward the cortex, where they are found during adulthood. 11 Hence, activation of microglia that are normally present in the white matter tracts may make the fetal brain particularly vulnerable for white matter injury during gestation and around term.
Detection of activated microglial cells in vivo can provide valuable information about the degree of injury sustained in the perinatal period. Neonates born to mothers with chorioamnionitis, either diagnosed clinically or by placental histopathology, can be screened by PET imaging with [ 11 C](R)PK11195 for the presence of activated microglial cells as an indicator of neuroinflammation and hence possible predictor for the development of brain injury secondary to intrauterine infection. Although large radiation exposures in the neonatal period are a matter for concern, with regard to the radiation dose, [ 11 C](R)PK11195 scans in neonates could be accomplished using effective doses approximately equal to the yearly background radiation exposure, and less than or ]PK11195 uptake in coronal sections of the rabbit brain for the first 10 minutes of the scan and the last 10 minutes of the scan at day 1 of life. Three-dimensional ROI (indicated by dotted lines) were drawn for the whole brain. The activity in the brain decreases over time for the saline-injected control pups from 0 to 10 minutes of the scan when compared with 50 to 60 minutes of the scan, while it increases over time for the newborn rabbit pups exposed to endotoxin in utero, indicating specific binding of the tracer to activated microglial cells in the endotoxin-exposed pups. White arrows indicate fiducial markers used for coregistration of PET with magnetic resonance images. equal to the exposure of a clinical computed tomography (CT) scan of the head. Computed tomography scans currently result in an effective dose of around 30 millisievert (mSv) to 90 mSv (3.0 roentgen equivalents man [rem]-9.0 rem) per scan to the organ scanned. 96 At these doses in the newborn period, there is a small risk of radiationassociated cancer of around 0.04% to 0.06% lifetime attributable risk. 96 This risk decreases substantially with a decrease in the dose used.
With the PET scan, the typical neonatal doses would be around 5 mSv, which is 6 to 18 times less than that reported with CT scans. Given the very serious debilitating consequences of the development of cerebral palsy from perinatal brain injury, PET scanning for early detection of neuroinflammation in the neonate may potentially have a high benefit-to-risk ratio. A noninvasive technique that would help detect the presence and progress of neuroinflammation at a very early stage would be beneficial in directing relevant supportive therapies and follow-up for these patients. Judicious use of PET scanning in the neonatal period would also eventually help in the development of early therapeutic interventions that can be directed toward these patients.
Conclusion
Molecular imaging of the peripheral benzodiazepine receptor provides a unique approach for detecting the Figure 3 . A, Tomato lectin staining of microglial cells in postnatal day 1 brain of rabbit kits born to dams injected intrauterinely with (a) saline (control) and (b) 20 ug/kg lipopolysaccharide (endotoxin). Microglia in the control group exhibits ramified morphology (a, arrow), whereas in the endotoxin group the processes are shorter and thicker (a, arrow). An increase in the density of ameboid microglial cells in the endotoxin-treated group was noted when compared with the control group. Scale bar ¼ 50 mm. B, Tomato lectin staining of microglia in postnatal day 1 control and endotoxinexposed kits. Representative images indicate a robust increase in microglial cells along the border of lateral ventricle, internal capsule, and corpus callosum in the endotoxin kit when compared with control. Scale bar ¼ 200 mm.
presence and extent of brain injury in various neurodegenerative and neuroinflammatory disorders. Although there has been increased interest in PET imaging for detection of neurodegenerative disorders in adults and older children, its potential applications in the neonatal period and during infancy have not been explored adequately. Positron emission tomography imaging for detection of neuroinflammation can be a valuable tool for noninvasively diagnosing the presence and extent of brain injury in newborns exposed to intrauterine insults. When used in conjunction with diffusion tensor imaging or magnetic resonance spectroscopy, it can be used to detect subtle changes in the central nervous system that may not be obvious by conventional imaging techniques. Positron emission tomography imaging of neuroinflammation may be useful as a prognostic indicator for the development of white matter injury and cerebral palsy and can also provide valuable information for monitoring the response to therapeutic strategies.
